Canadian National Cancer Institute

We are grateful to Lisa Lindqvist for helpful comments on the manuscript. R. C. is supported by a CIHR Cancer Consortium Post-doctoral Training Grant Award. Work in the laboratory is supported by grants from the Canadian Institutes of Health Research, National Cancer Institute of Canada, and NIH (CA114475). 

Research on kallikreins in Dr. Diamandis s laboratory has been funded in part by grants from the U.S. National Cancer Institute, the Early Detection Research Network, the Canadian Institutes of Health Research, the National Cancer Institute of Canada, the Natural Sciences and Engineering Research Council of Canada, and IBEX Technologies Inc., Montreal, Canada. 

We sincerely thank the Steacie Institute for Molecular Sciences (SIMS), the National Research Council of Canada s Genomics and Health Initiative (NRCC-GHI), the Canadian Institutes of Health Research (CIHR), and the National Cancer Institute of Canada (NCIC) for their continued support of this research. Our thanks to several former and current group members and collaborators for their numerous highly valuable contributions made to the work discussed in this chapter. 

The author acknowledges the support of the US Department of Defense Breast Cancer Research Program, the Canadian Institutes of Health Research, the Canada Foundation for Innovation, the National Cancer Institute of Canada and the Susan G. Komen Breast Cancer Foundation in providing funds for research described in this chapter originating in his laboratory at the University of Toronto. 

An article in the September 25, 1995, issue of Maclean s Magazine, written by Patricia Chisholm and titled Healers or Quacks, noted that in a 1989 Health Canada Bulletin, a trial carried out in 1982 by 112 Canadian doctors found Essiac to be of no benefit, and the National Cancer Institute (NCI) judged similarly in 1983. As for the efficacy of the Essiac tea, it should also depend upon whether the plant sources are of the correct species and are suitably active. This, therefore becomes a quandary within a quandary. 

The author wishes to thank the following agencies for supporting some of the work illustrated here the National Cancer Institute of Canada ( O2 dosimetry and OCT monitoring), the National Institutes of Heath, US (CA-43892) (brain and prostate cancer PDT, metronomic PDT and BLI ), the Canadian Institute for Photonic Innovations (2-photon PDT) and Photonics Research Ontario (PDT technology development). Also, thanks to colleagues and students who have contributed to the PDT research program at the Ontario Cancer Institute and to our many clinical collaborators. 

---